Meller, Birgit

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T11:24:50Z"],["dc.date.available","2018-11-07T11:24:50Z"],["dc.date.issued","2009"],["dc.format.extent","S404"],["dc.identifier.isi","000208690802128"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56493"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Labelling of the bispecific trivalent monoclonal antibody TF2 and the TF2 binding hapten IMP288 for in vitro and in vivo investigations in colorectal cancer (Immuno SPET, PET and radioimmuno therapy)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Sharkey, R. M."],["dc.contributor.author","Goldenberg, David M."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T08:51:26Z"],["dc.date.available","2018-11-07T08:51:26Z"],["dc.date.issued","2011"],["dc.format.extent","S243"],["dc.identifier.isi","000208619400553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/21933"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Automatized Ga-68-Labeling of the Hapten-Peptide, IMP288, for Radioimmuno-PET Trials to Evaluate Therapeutic Response"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1226"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1231"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Rades, Dirk"],["dc.contributor.author","Wolff, Christian"],["dc.contributor.author","Nadrowitz, Roger"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Schild, Steven E."],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T11:22:04Z"],["dc.date.available","2018-11-07T11:22:04Z"],["dc.date.issued","2009"],["dc.description.abstract","Purpose: Systemic therapies when added to whole brain radiotherapy have failed to improve the survival of patient h multiple brain metastases. The epidermal growth factor receptor antibody cetuximab is an attractive option, if it is able to cross the blood-brain barrier. This might be proven with molecular imaging if the radiolabeled antibody is stable long enough to be effective. This study investigated the stability of radiolabeled cetuximab (Erbitux) ((131)I-Erbi) and potential synergistic effects with radiotherapy in vitro. Methods and Materials: Two cell lines were investigated, A431 with numerous epidermal growth factor receptors, and JIMT without epidermal growth factor receptors. We labeled 0.4 mg cetuximab with 50 MBq of [(131)I] iodide. Stability was determined for 72 h. The cell cultures were incubated with (131)I-Erbi or cold cetuximab for 72 h. Uptake and cell proliferation were measured every 24 h after no radiotherapy or irradiation with 2, 4, or 10 Gy. Results: The radiolabeling yield of (131)I-Erbi was always >80%. The radiochemical purity was still 93.6% after 72 h. A431 cells showed a (131)I-Erbi uptake about 100-fold greater than the JIMT controls. After 48 h, the A431 cultures showed significantly decreased proliferation. At 72 h after irradiation, (131)I-Erbi resulted in more pronounced inhibition of cell proliferation than the cold antibody in all radiation dose groups. Conclusion: (131)I-Erbi was stable for <= 72 h. Radiotherapy led to increased tumor cell uptake of (131)I-Erbi. Radiotherapy and (131)I-Erbi synergistically inhibited tumor cell proliferation. These results provide the prerequisite data for a planned in vivo study of whole brain radiotherapy plus cetuximab for brain metastases. (C) 2009 Elsevier Inc."],["dc.description.sponsorship","German Research Society (DFG) [KFO 179]"],["dc.identifier.doi","10.1016/j.ijrobp.2008.12.029"],["dc.identifier.isi","000271489600040"],["dc.identifier.pmid","19356858"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55918"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","0360-3016"],["dc.title","RADIOACTIVE EGFR ANTIBODY CETUXIMAB IN MULTIMODAL CANCER TREATMENT: STABILITY AND SYNERGISTIC EFFECTS WITH RADIOTHERAPY"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Flaemig, L."],["dc.contributor.author","Bache, M."],["dc.contributor.author","Odparlik, A."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Vordermark, Dirk"],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, Birgit"],["dc.date.accessioned","2018-11-07T09:19:16Z"],["dc.date.available","2018-11-07T09:19:16Z"],["dc.date.issued","2013"],["dc.format.extent","S160"],["dc.identifier.isi","000325853400198"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28594"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)"],["dc.relation.eventlocation","Lyon, FRANCE"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Biological effects of positron emitters in thyroid cell cultures"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Nadrowitz, R."],["dc.contributor.author","Rades, Dirk"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T08:38:10Z"],["dc.date.available","2018-11-07T08:38:10Z"],["dc.date.issued","2010"],["dc.format.extent","S289"],["dc.identifier.isi","000283023800405"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18704"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)"],["dc.relation.eventlocation","Vienna, AUSTRIA"],["dc.relation.issn","1619-7070"],["dc.title","Influence of external irradiation on epidermal growth factor receptor (EGFR) - mediated antibody uptake in colorectal cancer cells"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","N23"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","N25"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.contributor.author","Horstmann, Olaf"],["dc.contributor.author","Gerl, J."],["dc.contributor.author","Baehre, Manfred"],["dc.contributor.author","Meller, J."],["dc.date.accessioned","2018-11-07T08:44:54Z"],["dc.date.available","2018-11-07T08:44:54Z"],["dc.date.issued","2005"],["dc.identifier.isi","000230201000008"],["dc.identifier.pmid","15997503"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20302"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Conventional gamma and high energy probe for radioguided dissection of metastases in a patient with recurrent thyroid carcinoma with Tc-99m-MIBI and F-18-FDG"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","243"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Nuklearmedizin"],["dc.bibliographiccitation.lastpage","248"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","von Hof, K."],["dc.contributor.author","Genina, E."],["dc.contributor.author","Deisting, W."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Richter, E."],["dc.contributor.author","Baehre, Manfred"],["dc.date.accessioned","2018-11-07T08:44:51Z"],["dc.date.available","2018-11-07T08:44:51Z"],["dc.date.issued","2005"],["dc.description.abstract","Aim: Urinary iodine excretion (UIE) provides information about iodine supply and release. lathe present study we investigated effects of the application of different radioiodine isotopes on UIE in patients with differentiated thyroid carcinoma (DTC). Patients, methods: In 91 consecutive patients with DTC UIE, measured as iodine/creatinine ratio, was determined before and after application of I-123 and I-131 for diagnostic or therapeutic purposes. Additionally, remnant volume (V) was determined prior to therapy. Group A consisted of 33 patients with supposed successful ablation of DTC. These patients received 370 MBq I-131 for diagnostic use and served as controls. 58 patients (group B) with remnants, relapses and metastases received 370 MBq I-123 for diagnostics prior to therapy with 1.5-22.2 GBq I-131. Factors influencing individual changes in urinary iodine excretion (Delta UIE) were investigated by using non-parametric tests. Results: In group A WE did not change significantly after application of I-131. As well, UIE remained unchanged after diagnostic application of I-123 in group B. In contrast, UIE increased significantly already 24 h after therapeutic application of I-131 in this group. In patients with small remnants (V < 2.5 ml) a significant but only moderate increase of WE could be observed (average increase: 47 mu g l/g crea). In patients with larger remnants, with relapses or metastases increase of UIE values was significant and more pronounced. Conclusions: It was confirmed that UIE increased significantly during radioiodine therapy in patients with DTC and radioiodine-accumulating tissue. The increase of WE after therapeutic administration of radioiodine can be explained by the disintegrated thyroid follicles in thyroid remnants. The radioiodine-induced iodine release may be one reason for thyroid \"stunning\" even after application of diagnostic amounts of I-131."],["dc.identifier.isi","000234213400004"],["dc.identifier.pmid","16400384"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20291"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Schattauer Gmbh-verlag Medizin Naturwissenschaften"],["dc.relation.issn","0029-5566"],["dc.title","Diagnostic I-121 and I-131 activities and radioiodine therapy - Effects on urinary iodine excretion in patients with differentiated thyroid carcinoma"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S354"],["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.lastpage","S355"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Huettl, Katrin"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Meller, J."],["dc.contributor.author","Baehre, Manfred"],["dc.date.accessioned","2018-11-07T09:05:01Z"],["dc.date.available","2018-11-07T09:05:01Z"],["dc.date.issued","2012"],["dc.identifier.isi","000309726601200"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/25228"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.conference","25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM)"],["dc.relation.eventlocation","Milan, ITALY"],["dc.relation.issn","1619-7070"],["dc.title","Modulation of CEA-mediated radioimmuno uptake by co-application of tyrosine kinase inhibitors in vitro"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","30"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","36"],["dc.bibliographiccitation.volume","182"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Deisting, W."],["dc.contributor.author","Wenzel, B. E."],["dc.contributor.author","Pethel, A."],["dc.contributor.author","Nadrowitz, R."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Richter, E."],["dc.contributor.author","Baehre, Manfred"],["dc.date.accessioned","2018-11-07T10:42:40Z"],["dc.date.available","2018-11-07T10:42:40Z"],["dc.date.issued","2006"],["dc.description.abstract","Background: Radioiodine uptake (RIU) is one of the main prognostic factors for curative results of radioiodine therapy in patients with differentiated thyroid cancer. Some days after application of I-131, the uptake of a subsequent administration of radioiodine was found to be reduced. In contrast, early after irradiation with high-energy photons glucose and amino acid uptake were observed to be increased. Effects of external irradiation on RIU of thyrocytes using high-energy photons have not been investigated so far. Material and Methods: Two different cell lines (FRTL-5 and ML-1 cells) derived from thyroid tissue were studied in vitro. Cell Lines were either incubated with I-131 only (controls) or additionally irradiated with single doses of 6 or 10 Gy of high-energy photons using a linear accelerator. Cell number and RIU were determined 24-96 h after I-131 application. RIU measurements were repeated after application of sodium perchlorate in excess to investigate specificity of the uptake. Statistical analyses were performed using non-parametric tests. Results: Incubation with radioiodine as well as irradiation with high-energy photons slowed down proliferation in investigated cell lines significantly. Irradiation with solely I-131 resulted in stable or slightly decreased iodide uptake. Compared to those cells, the RIU increased significantly in externally irradiated cells, i.e., additional irradiation with 10 Gy resulted in an almost threefold increase of RIU in FRTL-5 after 72 h. The increase of RIU after irradiation was dose-dependent in both cell lines and could be blocked by perchlorate excess. Conclusion: It could be demonstrated that external irradiation increases RIU in thyroid cell cultures early after irradiation. The increase was dose-dependent and specific, as it could be blocked by perchlorate. This effect appears to be similar to the increase of other actively transported substances after irradiation with high-energy photons. Therefore, the results of this study may contribute to the knowledge of a generalized irradiation-induced mechanism which causes the activation of different cellular transporters. The clinical impact of these findings on combined therapy concepts has to be investigated in further experiments."],["dc.identifier.doi","10.1007/s00066-006-1442-y"],["dc.identifier.isi","000234943400005"],["dc.identifier.pmid","16404518"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/46857"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","Increased radioiodine uptake of thyroid cell cultures after external irradiation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Breunig, Christian"],["dc.contributor.author","Angerstein, C."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Baehre, Manfred"],["dc.date.accessioned","2018-11-07T11:24:50Z"],["dc.date.available","2018-11-07T11:24:50Z"],["dc.date.issued","2009"],["dc.format.extent","S251"],["dc.identifier.isi","000208690800440"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56494"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","New york"],["dc.relation.issn","1619-7070"],["dc.title","Changes of carcino embryonic antigen (CEA) mediated uptake of a CEA-specific pretargeting system in colorectal cancer in vitro after external irradiation"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]